31 results match your criteria: "University of California San Diego and Rady Children's Hospital San Diego[Affiliation]"

Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic disorder due to pathogenic variants in the COL7A1 gene. In this study we determined the association between different categories of COL7A1 variants and clinical disease severity in 236 RDEB patients in North America. Published reports or in-silico predictions were used to assess the impact of pathogenic variants in COL7A1 on type VII collagen (C7) protein function.

View Article and Find Full Text PDF

Of 319 children with invasive candidiasis, 67 (21%) transitioned from intravenous to enteral antifungal therapy. Eight (12%) transitioned back to intravenous antifungal therapy, one due to perceived treatment failure defined by clinical progression or worsening. Global treatment response at study completion was successful in 66 participants who transitioned to enteral therapy.

View Article and Find Full Text PDF

Background: Isolated psychiatric symptoms can be the initial symptom of pediatric anti-N-methyl-d-aspartate (NMDA) receptor autoimmune encephalitis (pNMDARE). Here we report on the prevalence of isolated psychiatric symptoms in pNMDARE. We also assess whether initial neurodiagnostic tests (brain magnetic resonance imaging [MRI], electroencephalography [EEG], and/or cerebrospinal fluid [CSF] white blood cell count) are abnormal in children with isolated psychiatric symptoms and pNMDARE.

View Article and Find Full Text PDF
Article Synopsis
  • - Abrocitinib is an FDA-approved oral medication for treating moderate-to-severe atopic dermatitis (AD) in both adults and adolescents, and it has proven to be effective in clinical trials with a good safety profile over time.
  • - A 200-mg daily dose of abrocitinib offers quicker relief from itching and better skin improvement compared to dupilumab, but monitoring for potential side effects is crucial due to risks associated with all oral JAK inhibitors.
  • - The use of abrocitinib is appropriate for qualified patients needing systemic AD therapy, though caution is advised for specific populations such as older adults and those with certain health risks, with a recommendation to start with a lower 100-mg dose in
View Article and Find Full Text PDF
Article Synopsis
  • The 2021 approval of ruxolitinib cream for treating atopic dermatitis (AD) in patients aged 12 and older was supported by phase 3 studies, but real-world effectiveness and physician satisfaction data are limited.
  • A study analyzing data from 1360 patients indicated that 149 received ruxolitinib cream for at least one month, with significant improvements in skin condition observed—only 21.5% remained with moderate AD after treatment.
  • Physician satisfaction regarding disease control was high at 87.3%, and the primary reasons for prescribing ruxolitinib cream included relieving itch and improving the appearance of lesions.
View Article and Find Full Text PDF

Human milk is the optimal form of nutrition for infants. Interventions associated with a decreased rate of exposure to infant formula are of benefit. We hypothesized that intravenous (IV) fluids could be associated with a reduction of infant formula when infants are separated from their mother.

View Article and Find Full Text PDF
Article Synopsis
  • Crisaborole ointment, a nonsteroidal treatment for mild-to-moderate atopic dermatitis (AD), was evaluated for efficacy and safety in patients with various treatment histories.
  • In a study involving patients aged 2 and older, those treated with crisaborole showed significantly better outcomes on assessment tools compared to those receiving a placebo.
  • Overall, crisaborole was well tolerated and displayed a promising efficacy and safety profile in both experienced and treatment-naive patients.
View Article and Find Full Text PDF
Article Synopsis
  • Updated guidelines revise the 2014 recommendations for managing atopic dermatitis (AD) using phototherapy and systemic therapies.
  • A multidisciplinary team systematically reviewed evidence and used the GRADE approach to create 11 recommendations for adult AD management.
  • Strong support was found for biologic and immunomodulatory treatments like dupilumab and abrocitinib, while phototherapy and certain medications received conditional support, and systemic corticosteroids were not recommended.
View Article and Find Full Text PDF
Article Synopsis
  • The text discusses updated guidelines for treating atopic dermatitis (AD) in adults, particularly using phototherapy and systemic therapies since multiple new treatments were approved after 2014.* -
  • A multidisciplinary workgroup established 11 evidence-based recommendations, emphasizing strong support for biologics and oral JAK inhibitors, while recommending caution with systemic corticosteroids.* -
  • Limitations in the review highlight that many trials are short-term, which hampers the assessment of long-term effectiveness and safety for these treatments.*
View Article and Find Full Text PDF

Background: Adjunctive diagnostic studies (aDS) are recommended to identify occult dissemination in patients with candidemia. Patterns of evaluation with aDS across pediatric settings are unknown.

Methods: Candidemia episodes were included in a secondary analysis of a multicenter comparative effectiveness study that prospectively enrolled participants age 120 days to 17 years with invasive candidiasis (predominantly candidemia) from 2014 to 2017.

View Article and Find Full Text PDF
Article Synopsis
  • * Tralokinumab is a new monoclonal antibody that targets IL-13, showing significant improvements in AD symptoms in three phase 3 clinical trials, both alone and with topical corticosteroids.
  • * Treatment with tralokinumab leads to noticeable symptom relief, including reduced itch and better sleep, while maintaining a safety profile similar to a placebo, making it a strong new option for managing moderate-to-severe AD.
View Article and Find Full Text PDF

MRI Features and Their Association With Outcomes in Children With Anti-NMDA Receptor Encephalitis.

Neurol Neuroimmunol Neuroinflamm

July 2023

From the Emory University SOM and Children's Healthcare of Atlanta (G.G., M. Morris); University of Virginia Health System (J.N.B.); University of California San Diego and Rady Children's Hospital San Diego (J.H.Y.); Boston Children's Hospital and Harvard Medical School (C.M.S., M.G.); University of Colorado SOM and Children's Hospital Colorado (R.K.); Seattle Children's/University of Washington (C.E.O.); Vanderbilt University Medical Center (N.V.); Children's Hospital Los Angeles and Keck School of Medicine (J.D.S.), University of Southern California; University of Texas at Austin and Dell Medical School (K.R.-L., M. Moodley, D.H.); New York University SOM (A.C., C.S.); Children's National Hospital and George Washington University Medical School (A.B.K., I.K., L.N.S.); Mount Sinai University and Bristol Myers Squibb (A.Y.).

Article Synopsis
  • The study investigates the relationship between MRI lesions and clinical outcomes in children with anti-NMDA receptor encephalitis (pNMDARE).
  • A total of 175 children were examined, and it was found that those with abnormal T2-hyperintense lesions, especially in the frontal and occipital lobes, had worse outcomes after one year.
  • Although the initial association between MRI features and poor outcomes weakened after certain adjustments, further analysis indicated that specific brain lesions could still serve as potential predictors for prognosis in future studies.
View Article and Find Full Text PDF

Background: Topical treatments for atopic dermatitis (AD) used reactively often fail to achieve lasting disease control; many of these therapies are associated with safety concerns that limit long-term use. Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate AD that has potential as a long-term maintenance therapy.

Objective: The aim was to evaluate the long-term efficacy and safety of crisaborole once daily (QD) compared to vehicle QD as a maintenance therapy to reduce the incidence of flares in patients with AD who previously responded to crisaborole twice daily (BID).

View Article and Find Full Text PDF

Mitochondrial dysfunction associated with TANGO2 deficiency.

Sci Rep

February 2022

Division of Genetic and Genomic Medicine, Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA.

Transport and Golgi Organization protein 2 Homolog (TANGO2)-related disease is an autosomal recessive disorder caused by mutations in the TANGO2 gene. Symptoms typically manifest in early childhood and include developmental delay, stress-induced episodic rhabdomyolysis, and cardiac arrhythmias, along with severe metabolic crises including hypoglycemia, lactic acidosis, and hyperammonemia. Severity varies among and within families.

View Article and Find Full Text PDF

Objective: To provide guidance on the management of Multisystem Inflammatory Syndrome in Children (MIS-C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of SARS-CoV-2 infection. Recommendations are also provided for children with hyperinflammation during COVID-19, the acute, infectious phase of SARS-CoV-2 infection.

Methods: The Task Force is composed of 9 pediatric rheumatologists and 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician.

View Article and Find Full Text PDF

Background: Understanding the clinical course and short-term outcomes of suspected myocarditis after the coronavirus disease 2019 (COVID-19) vaccination has important public health implications in the decision to vaccinate youth.

Methods: We retrospectively collected data on patients <21 years old presenting before July 4, 2021, with suspected myocarditis within 30 days of COVID-19 vaccination. Lake Louise criteria were used for cardiac MRI findings.

View Article and Find Full Text PDF

In a single-site study (San Diego, CA, USA), we previously showed that Kawasaki Disease (KD) cases cluster temporally in bursts of approximately 7 days. These clusters occurred more often than would be expected at random even after accounting for long-term trends and seasonality. This finding raised the question of whether other locations around the world experience similar temporal clusters of KD that might offer clues to disease etiology.

View Article and Find Full Text PDF

Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies.

J Clin Endocrinol Metab

October 2021

Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, MI and Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA.

Context: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is typically treated with lifelong supraphysiologic doses of glucocorticoids (GCs). Tildacerfont, a corticotropin-releasing factor type-1 receptor antagonist, may reduce excess androgen production, allowing for GC dose reduction.

Objective: Assess tildacerfont safety and efficacy.

View Article and Find Full Text PDF

Objective: To provide guidance on the management of Multisystem Inflammatory Syndrome in Children (MIS-C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Recommendations are also provided for children with hyperinflammation during coronavirus disease 2019 (COVID-19), the acute, infectious phase of SARS-CoV-2 infection.

Methods: The Task Force was composed of 9 pediatric rheumatologists and 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician.

View Article and Find Full Text PDF

Background: Kratom is a psychoactive substance that is isolated from the plant . The leaves can be chewed fresh or dried, smoked, or infused similar to herbal teas. The plant leaves have been used by natives of Southeast Asia for centuries.

View Article and Find Full Text PDF

Objective: To provide guidance on the management of multisystem inflammatory syndrome in children (MIS-C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and to provide recommendations for children with hyperinflammation during coronavirus disease 2019 (COVID-19), the acute, infectious phase of SARS-CoV-2 infection.

Methods: A multidisciplinary task force was convened by the American College of Rheumatology (ACR) to provide guidance on the management of MIS-C associated with SARS-CoV-2 and hyperinflammation in COVID-19. The task force was composed of 9 pediatric rheumatologists, 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician.

View Article and Find Full Text PDF

1p36 deletion syndrome is a well-described condition with a recognizable phenotype, including cognitive impairment, seizures, and structural brain anomalies such as periventricular leukomalacia (PVL). In a large series of these individuals by Battaglia et al., "birth history was notable in 50% of the cases for varying degrees of perinatal distress.

View Article and Find Full Text PDF

Intersectionality has become a significant intellectual approach for those thinking about the ways that race, gender, and other social identities converge in order to create unique forms of oppression. Although the initial work on intersectionality addressed the unique position of black women relative to both black men and white women, the concept has since been expanded to address a range of social identities. Here we consider how to apply some of the theoretical tools provided by intersectionality to the clinical context.

View Article and Find Full Text PDF